Colossal Biosciences
Colossal Biosciences raises $200M Series C at $10.2B valuation
Colossal Biosciences: Series C Funding Round
Colossal Biosciences has successfully raised $200M in Series C funding, reaching a valuation of $10.2B.
Company Overview
De-extinction and genetic engineering
Funding Details
The Series C round was led by Breyer Capital, with participation from In-Q-Tel, Tony Robbins.
Company Information
- Headquarters: Dallas, TX
- Founded: 2021
- Employees: 150+
- Category: Biotech
Investment
Colossal Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Breyer Capital: Verified investor in Series C
- In-Q-Tel: Verified investor in Series C
- Tony Robbins: Verified investor in Series C
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free